The floor price was set at ₹1,279.80 per share, as per sources.
At the end of the March quarter, BC Investments IV Ltd. held 8.68% stake in the company.
Emcure Pharmaceuticals reported a 63% rise in consolidated profit after tax (PAT) to ₹197 crore during the March quarter. The Pune-headquartered firm reported a profit after tax (PAT) of ₹121 crore on a consolidated basis a year ago.During the January-March period, Emcure Pharmaceuticals’ revenue from operations stood at ₹2,116 crore, up 19.5% year-on-year from ₹1,771 crore. In a statement, the company said the quarter saw strong performance across both its domestic and international businesses.
Emcure’s domestic business grew 24.8% year-on-year, led by its women’s health and cardio franchises. Meanwhile, the international business registered a growth of 15.6%. In Europe, we recently acquired a portfolio of products and secured key regulatory approvals, which will aid growth going forward, Emcure Pharmaceuticals said.
Emcure Pharmaceuticals Ltd CEO and Managing Director Satish Mehta said, “Over the past year, we have effectively executed our strategies across both domestic and international markets. On the domestic side, we have expanded our covered market and built a strong product pipeline of upcoming launches.”
Emcure Pharma shares were down 1.63% at ₹1,259 apiece at 9.20 am. The stock has declined 13.4% this year, so far.
Also Read: Trent shares tank 9% after warning of slower growth in AGM, analyst downgrades
